H1, a company on a mission to connect the world with the right doctors, announced several key milestones. H1 is strengthening its leadership team by appointing former FDA Commissioner Dr. Stephen M. Hahn to its board, and the company announced the strategic acquisition of Ribbon Health and unveiled a series of innovative products.
As part of its continued growth, H1 has also welcomed Dr. Stephen Hahn to its Board of Directors. And Dr. Hahn is a distinguished physician, scientist, and healthcare leader with oncology, clinical research, and executive leadership expertise.
As the FDA Commissioner from 2019-2021 under the Trump administration, Dr. Hahn oversaw regulatory affairs for COVID-19 and non-COVID-related areas, including therapeutics, vaccine development, medical devices, diagnostics, and clinical trials. And he currently serves as CEO of Harbinger Health, where he spearheads early-stage cancer detection. With 220+ published research articles, Dr. Hahn brings deep experience across patient care, clinical trials, and medical product development.
Ribbon Health Acquisition
H1 entered a definitive agreement to acquire Ribbon Health on December 12th, 2024. Backed by notable investors, including General Catalyst, Andreessen Horowitz (a16z), BoxGroup, Rock Health, and Sachin Jain, Ribbon’s platform facilitates how patients find the right doctor across digital health and insurance platforms.
This acquisition advances H1’s goal by fueling its expansion into the health plan, provider system, and digital health sectors. And Ribbon Health’s platform will join the H1 family of products as H1 for Health Plans & Digital Health, providing insurers, providers, and digital health companies alike with accurate, real-time provider data.
Along with H1 for Health Plans & Digital Health, H1 is unveiling a refined product vision to address the evolving needs of its customers and the market—all powered by its award-winning, AI-driven data and analytics platform:
— H1 for Medical helps medical affairs teams identify and engage Key Opinion Leaders (KOLs) to promote adherence to evidence-based medicine.
— H1 for Clinical supports clinical teams in identifying sites, principal investigators (PIs), and participants while advancing diversity, equity, and inclusion in the trial process.
— H1 for Commercial accelerates patient access by facilitating the development and successful launch of new medical therapies and technologies.
While designed for stand-alone use, these solutions create a seamless system that streamlines processes and improves diversity across the entire pharmaceutical lifecycle when used together.
KEY QUOTES:
“H1 continues to live its mission by connecting the world with the right doctors. By adding Dr. Hahn, with his deep expertise and impressive credentials, to our leadership team and expanding our portfolio through the development of new products and the acquisition of Ribbon Health, we’re confident we have everything in place to accomplish that mission.”
– Ariel Katz, co-founder and CEO of H1
“I’m excited to join H1’s board at such a pivotal time in healthcare innovation. H1’s commitment to leveraging data and technology to improve healthcare access and outcomes aligns with my lifelong passion for advancing care and clinical research. I look forward to lending my skills to help H1 progress its mission.”
– Dr. Hahn
“From the moment Ariel and I first met, it was clear that Ribbon and H1 were destined to collaborate. Our platforms—and our visions—mesh perfectly. By combining our comprehensive provider data and provider data management software with H1’s clinical insights and global reach, we’re giving individuals the information they need to get the best possible care.”
– Nate Maslak, co-founder and CEO, Ribbon Health
